31 results about "Inappropriate secretion" patented technology

The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a beta-blocker and to combinations useful therefor. The methods, compositions and combinations of the present invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke). The methods, compositions and combinations of the present invention can also be used for the treatment and / or prevention of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin inappropriate secretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokalemia, polycystic kidney disease, diabetes, or circulation disorder.

The present invention is concerned with spiro-dihydrotetraazabenzoazulenes, i.e. spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula I wherein R1, R2, R3, X, Y, Z, m and n are as described herein. The compounds according to the invention act as V1a receptor modulators and are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention relates to heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with aryl- / heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1 a receptor modulators, and in particular as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein.The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The compounds are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention relates to triazole derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such triazole derivatives. Said triazoles are useful in the treatment and / or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to triazole derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and / or vasopressin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin and / or vasopressin. The present invention is furthermore related to novel triazole derivatives as well as to methods of their preparation.

The present invention relates to sulfanilide derivatives of formula (I), in which R1 and R2 are optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and / or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and / or vasopressin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin and / or vasopressin, including preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. The present invention is furthermore related to novel sulfanilide derivatives as well as to methods of their preparation.

The invention relates to application of twotooth achyranthes aqueous extract to preparation of estrogen medicines. By the twotooth achyranthes aqueous extract, medicines for treating diseases caused by inappropriate secretion of estrogen in a human body can be effectively prepared. According to the technical scheme, twotooth achyranthes is decocted in water in an amount which is 10 times the weight of twotooth achyranthes twice, for two hours each time, water decoctions which are obtained twice are mixed, and the mixed water decoction is concentrated under reduction pressure and dried to form twotooth achyranthes extractum aqueous extract; the twotooth achyranthes aqueous extract can be effectively used for preparing medicines for preventing relevant diseases caused by inappropriate secretion of estrogen in the human body, so that the application of the twotooth achyranthes aqueous extract to preparation of the medicines for treating the relevant diseases caused by the inappropriate secretion of estrogen in the human body can be realized; a preparation method for the aqueous extract is simple, stable and reliable; through multiple times of experiments, the same or similar results are obtained; the method is convenient and low in cost; and the aqueous extract can be effectively used for preparing the estrogen medicines, new medicinal application of twotooth achyranthes is developed, and great clinical significance is brought.

The present invention is concerned with alkylcyclohexylethers of dihydro-tetraazabenzoazulenes, i.e. alkylcyclohexylethers of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene s of formula Iwherein R1, R2 and R3 are as described herein, their manufacture, and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The compounds are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The invention discloses a compound Chinese herbal capsule for diabetes mellitus and a preparation method thereof. The capsule includes, by weight ratio, 20-35 g of hairyvein agrimonia herb, 30-45 g oflotus plumule, 20-35 g of stiff silkworm, 25-40 g of Chinese magnoliavine fruit, 20-25 g of earthworm, and 20-35 g of vietnamese sophora root. The capsule can restore the relative insufficiency of insulin secretion, or the function of glucose metabolism disorder caused by inappropriate secretion of insulin glucogon; the capsule has the efficacy of nourishing yin and moistening lung, clearing theheart and eliminating vexation, tonifying stomach and promoting fluid, nourishing liver and kidney, nourishing yin to moisten dryness, benefiting qi and clearing heat, promoting the production of bodyfluid to quench thirst, and promoting blood circulation and resolving phlegm; for type 2 diabetes mellitus, the capsule is small in dosage, fast in effectiveness, short in healing time, high in curative effect and small in side-effect; lifelong medication is not required after cure; blood sugar can be stable and does not rebound; and therefore, simultaneous treatment of principal and subordinatesymptoms can be achieved, the diabetes mellitus can be fundamentally cured, and effective rates can reach 95%, and cure rates can reach more than 84%.

The invention relates to application of Chinese wolfberry root-bark aqueous extract to preparation of estrogen medicines. By the Chinese wolfberry root-bark aqueous extract, medicines for treating diseases caused by inappropriate secretion of estrogen in a human body can be effectively prepared. According to the technical scheme, Chinese wolfberry root-bark is decocted in water in an amount which is 10 times the weight of water twice, for two hours each time, water decoctions obtained twice are mixed, and the mixed water decoction is concentrated under reduced pressure and dried to form Chinese wolfberry root-bark extractum aqueous extract; the Chinese wolfberry root-bark aqueous extract can be effectively used for preparing medicines for treating relevant diseases caused by inappropriate secretion of estrogen in the human body, so that the application of the Chinese wolfberry root-bark aqueous extract to the preparation of the medicines for treating the relevant diseases caused by the inappropriate secretion of estrogen in the human body, such as the application of the Chinese wolfberry root-bark aqueous extract to preparation of a medicine for treating climacteric syndrome of women can be realized; a preparation method for the aqueous extract is simple, stable and reliable; through multiple times of experiments, the same and similar results are obtained; the method is convenient and low in cost; and the aqueous extract can be effectively used for preparing the estrogen medicines, the new medicinal application of the Chinese wolfberry root-bark is developed, and great clinical significance is brought.

The present invention is concerned with arylcyclohexylethers of dihydro-tetraazabenzoazulenes, i.e. arylcyclohexylethers of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein, their manufacture, and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with aryl- / heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with arylcyclohexylethers of dihydro-tetraazabenzoazulenes, i.e. arylcyclohexylethers of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein, their manufacture, and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention relates to heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

Spiro-thiazolones of formula Iwherein X1, X2, X3, X4, R2, R3, R4, R5, R6 and R7 are as defined herein, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

The present invention relates to triazole derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such triazole derivatives. Said triazoles are useful in the treatment and / or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to triazole derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and / or vasopressin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin and / or vasopressin. The present invention is furthermore related to novel triazole derivatives as well as to methods of their preparation.

The invention relates to application of Chinese wolfberry root-bark aqueous extract to preparation of estrogen medicines. By the Chinese wolfberry root-bark aqueous extract, medicines for treating diseases caused by inappropriate secretion of estrogen in a human body can be effectively prepared. According to the technical scheme, Chinese wolfberry root-bark is decocted in water in an amount which is 10 times the weight of water twice, for two hours each time, water decoctions obtained twice are mixed, and the mixed water decoction is concentrated under reduced pressure and dried to form Chinese wolfberry root-bark extractum aqueous extract; the Chinese wolfberry root-bark aqueous extract can be effectively used for preparing medicines for treating relevant diseases caused by inappropriate secretion of estrogen in the human body, so that the application of the Chinese wolfberry root-bark aqueous extract to the preparation of the medicines for treating the relevant diseases caused by the inappropriate secretion of estrogen in the human body, such as the application of the Chinese wolfberry root-bark aqueous extract to preparation of a medicine for treating climacteric syndrome of women can be realized; a preparation method for the aqueous extract is simple, stable and reliable; through multiple times of experiments, the same and similar results are obtained; the method is convenient and low in cost; and the aqueous extract can be effectively used for preparing the estrogen medicines, the new medicinal application of the Chinese wolfberry root-bark is developed, and great clinical significance is brought.

The invention discloses hair blacking-conditioning powder and a preparation method thereof. The hair blacking-conditioning powder is prepared from the following raw materials in parts by weight: 40 to 65 parts of tea bran powder, 2 to 5 parts of rose, 5 to 10 parts of poria cocos, 5 to 8 parts of agastache rugosus, 10 to 20 parts of polygonum multiflorum, and 10 to 15 parts of eclipta. The preparation method comprises the following steps of weighing all the raw materials in parts by weight; respectively drying; and sterilizing to obtain the hair blacking-conditioning powder. The hair blacking-conditioning powder has the effects of promoting blood circulation, dispelling wind and activating collaterals and accordingly realizes the functions of fully conditioning hair follicle nutrition, supplementing nutrition for melanocyte, improving inappropriate secretion of hair follocle melanocyte, and avoiding premature graying of hair; all the raw materials coordinate to achieve the functions of promoting blood circulation of the scalp, providing sufficient nutrition to the scalp, hair and hair follicle and promoting the regeneration of melanophore of hair, and therefore, the effects of blacking hair, dispelling scurf and relieving itching are realized.

Spiro-thiazolones of formula Iwherein X1, X2, X3, X4, R2, R3, R4, R5, R6 and R7 are as defined herein, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The compounds are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention belongs to a traditional Chinese medicine, and specifically provides a traditional Chinese medicine for the treatment of inappropriate secretion of antidiuretic hormone. The medicine is characterized by comprising the following components: 8-12 grams of ophiopogon root, 8-12 grams of root of kudzu vine and 8-12 grams of Anemarrhena asphodeloides. According to the differentiation theory in traditional Chinese medicine, the medicine has the advantages of simple formulation, easily available materials, low cost, high curative effect, and no toxic or side effect in the treatment of inappropriate secretion of antidiuretic hormone.

The invention discloses a gland-stimulating massage method. The gland-stimulating massage method includes massaging channels and acupoints of the head, the face, the body and the limbs of a human body according to different positions of the eight glands of a human body endocrine system, thus effects of stimulating gland secretion, regulating and improving hormone level of the organism and improving immunity of the organism are achieved by stimulating corresponding channels and acupoints. Massage to the head and the face includes stimulating the epiphysis and the pituitary gland. Massage to the body includes stimulating the adrenal gland, the thymus gland and the pancreas. Massage to the limbs includes pressing effective acupoints for treating inappropriate secretion of the eight glands. By massing the channels and the acupoints, the gland-stimulating massage method has effects of improving gland secretion, immunity of the organism and body constitution, and also has functions of beautifying and body shaping, and particularly has effect in tightening skin effectively to achieve beautifying and body shaping.

The present invention is concerned with arylcyclohexylethers of dihydro-tetraazabenzoazulenes, i.e. arylcyclohexylethers of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein, their manufacture, and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention provides heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein.The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.